trehaloseWhat was measured
Measured, with no finding
46 endpoints
Show what was measuredHide what was measured
carbohydrate oxidation, drink
decreases
a reduced carbohydrate oxidation after trehalose when ingested as a drink
PMID 19664296 · one of two readings recorded this
fat oxidation, drink
no effect
no significant differences in fat oxidation between drink were observed
PMID 19664296 · one of two readings recorded this
glucose DeltaAUC with mixed meal
decreases
Ingestion of carbohydrates with a mixed meal resulted in a lower peak glucose response and a lower change in area under the curve (DeltaAUC) following trehalose when compared with glucose
PMID 19664296 · one of two readings recorded this
insulin DeltaAUC
unclear
Differences in peak insulin response and DeltaAUC were observed with trehalose when compared with glucose during the morning and afternoon
PMID 19664296 · one of two readings recorded this
peak glucose response with mixed meal
decreases
Ingestion of carbohydrates with a mixed meal resulted in a lower peak glucose response and a lower change in area under the curve (DeltaAUC) following trehalose when compared with glucose
PMID 19664296 · one of two readings recorded this
peak insulin response
unclear
Differences in peak insulin response and DeltaAUC were observed with trehalose when compared with glucose during the morning and afternoon
PMID 19664296 · one of two readings recorded this
Body mass
increases, p = 0.04
maltose: 72.8±3.4 vs. 72.1±3.4 kg, P=0.04; trehalose: 74.1±4.8 vs. 73.4±4.7 kg, P=0.02
PMID 27208415 · one of two readings recorded this
Body mass
increases, p = 0.02
maltose: 72.8±3.4 vs. 72.1±3.4 kg, P=0.04; trehalose: 74.1±4.8 vs. 73.4±4.7 kg, P=0.02
PMID 27208415 · one of two readings recorded this
Body mass, effect of time
increases, p = 0.01
There was a significant effect of time on body mass (F[2,27]=6.58, P=0.01)
PMID 27208415 · one of two readings recorded this
C-reactive protein
no effect
C-reactive protein (log10[mg/L]) | −0.21±0.08 | −0.15±0.08 | −0.23±0.09 | −0.27±0.10 | −0.16±0.13 | −0.17±0.11
PMID 27208415 · one of two readings recorded this
Carotid compliance (CC), group-by-time interaction
no effect, p = 0.39
this response did not differ between groups (F[1,26]=0.78, P=0.39)
PMID 27208415 · one of two readings recorded this
Carotid compliance (CC)
decreases, p = 0.03
a decline in CC with maltose supplementation (0.078±0.006 vs. 0.088±0.009 mm2/mmHg × 10−1, P=0.03)
PMID 27208415 · one of two readings recorded this
Carotid compliance (CC)
no effect, p = 0.12
there was not a significant within-group change in CC with trehalose (P=0.12, Figure 8)
PMID 27208415 · one of two readings recorded this
Carotid β-stiffness index
no effect, p = 0.1
no differences in β-stiffness index, a less blood pressure dependent measure of large elastic artery stiffness, was observed with either trehalose or maltose supplementation (both P>0.1, Figure 8)
PMID 27208415 · one of two readings recorded this
Change in body mass versus change in oxidized LDL
increases, p = 0.04
positive correlation between the change in body mass and the change in oxidized LDL after 12 weeks of supplementation (r=0.39, P=0.04)
PMID 27208415 · one of two readings recorded this
Circulating oxidized LDL, CRP, IL-6 and TNF-α, group-by-time interaction
no effect, p = 0.1
these factors did not change differentially across the intervention period in the maltose and trehalose treated groups (all P>0.1, Table 4)
PMID 27208415 · one of two readings recorded this
Energy intake, effect of time
unclear, p = 0.06
There was a trend towards a significant effect of time on energy intake in both groups (F[1,26]=3.83, P=0.06)
PMID 27208415 · one of two readings recorded this
Interleukin-6
no effect
Interleukin-6 (log10[pg/mL]) | −0.09±0.06 | −0.04±0.06 | −0.05±0.03 | −0.04±0.07 | −0.05±0.08 | −0.07±0.07
PMID 27208415 · one of two readings recorded this
Oxidized LDL change, group randomization controlling for body mass change
no effect, p = 0.33
group randomization was not an independent predictor of the change in oxidized LDL (r=0.18, P=0.33)
PMID 27208415 · one of two readings recorded this
Oxidized LDL
no effect
Oxidized LDL (U/L) | 46±5 | 42±4 | 42±3 | 45±3 | 44±4 | 46±4
PMID 27208415 · one of two readings recorded this
Percent body fat
no effect, p = 0.13
percent body fat did not change significantly across the intervention (F[1,29]=2.49, P=0.13)
PMID 27208415 · one of two readings recorded this
Relative carbohydrate intake
increases, p = 0.001
Relative carbohydrate intake was higher at week 12 vs. baseline in the maltose group (57±2 vs. 49±1% total calories, P<0.001)
PMID 27208415 · one of two readings recorded this
Relative carbohydrate intake
unclear, p = 0.07
there was a trend for carbohydrate intake to be elevated after 12 weeks of trehalose (55±2 vs. 50±3% total calories, P=0.07)
PMID 27208415 · one of two readings recorded this
Tumor necrosis factor-α
no effect
Tumor necrosis factor-α (log10[pg/mL]) | 0.09±0.03 | 0.13±0.03 | 0.12±0.04 | 0.03±0.05 | 0.08±0.04 | 0.09±0.05
PMID 27208415 · one of two readings recorded this
blood glucose concentration after 2-h oral glucose tolerance test
decreases
In the trehalose group, blood glucose concentrations after a 2-h oral glucose tolerance test significantly decreased following 12 wk of intake in comparison with baseline values (0 wk)
PMID 28202842 · one of two readings recorded this
change in body weight
decreases
the change in body weight, waist circumference, and systolic blood pressure were significantly lower in the trehalose group than in the sucrose group
PMID 28202842 · one of two readings recorded this
change in systolic blood pressure
decreases
the change in body weight, waist circumference, and systolic blood pressure were significantly lower in the trehalose group than in the sucrose group
PMID 28202842 · one of two readings recorded this
change in waist circumference
decreases
the change in body weight, waist circumference, and systolic blood pressure were significantly lower in the trehalose group than in the sucrose group
PMID 28202842 · one of two readings recorded this
change in alanine aminotransferase (ALT)
unclear
there was a significant difference between changes in alanine aminotransferase (ALT) trehalose and placebo groups
PMID 35045351 · one of two readings recorded this
change in cIMT from baseline
no effect
we could not demonstrate any significant difference between the trehalose group and control group in changes of cIMT from baseline to 3 months in the overall population
PMID 35045351 · one of two readings recorded this
change in MDS TBR of the index vessel (arterial wall inflammation, 18F-FDG PET/CT)
no effect
The MDS TBR change of the index vessel at 3-month follow-up was not significant in treatment and placebo groups
PMID 35045351 · one of two readings recorded this
echocardiographic measurements
no effect
No significant changes in echocardiographic measurement were noted after trehalose treatment
PMID 35045351 · one of two readings recorded this
urea level change
unclear, p = 0.038
Except for the change in urea level in placebo group (31.00 ± 6.59 vs. 25.60 ± 6.402 P = 0.038)
PMID 35045351 · one of two readings recorded this
blood glucose during the 100-min protocol
increases, p = 0.05
blood glucose was higher with maltodextrin compared with the other supplements at all time points (all p < .05)
PMID 38458180 · one of two readings recorded this
blood glucose during the 20-min time trial
no effect, p = 0.05
Heart rate, ratings of perceived exertion, muscle glycogen content, blood glucose, and lactate were not different between conditions when considering the 20-min time trial (all p > .05)
PMID 38458180 · one of two readings recorded this
blood lactate during the 20-min time trial
no effect, p = 0.05
Heart rate, ratings of perceived exertion, muscle glycogen content, blood glucose, and lactate were not different between conditions when considering the 20-min time trial (all p > .05)
PMID 38458180 · one of two readings recorded this
heart rate during the 20-min time trial
no effect, p = 0.05
Heart rate, ratings of perceived exertion, muscle glycogen content, blood glucose, and lactate were not different between conditions when considering the 20-min time trial (all p > .05)
PMID 38458180 · one of two readings recorded this
muscle glycogen content during the 20-min time trial
no effect, p = 0.05
Heart rate, ratings of perceived exertion, muscle glycogen content, blood glucose, and lactate were not different between conditions when considering the 20-min time trial (all p > .05)
PMID 38458180 · one of two readings recorded this
ratings of perceived exertion during the 20-min time trial
no effect, p = 0.05
Heart rate, ratings of perceived exertion, muscle glycogen content, blood glucose, and lactate were not different between conditions when considering the 20-min time trial (all p > .05)
PMID 38458180 · one of two readings recorded this
total work done, 20-min time trial
increases, p = 0.01
trehalose improved time-trial performance compared with placebo (total work done 302 ± 39 vs. 287 ± 48 kJ; p = .01)
PMID 38458180 · one of two readings recorded this
total work done, 20-min time trial
no effect, p = 0.07
with no other differences between sessions (all p ≥ .07)
PMID 38458180 · one of two readings recorded this
ataxia severity, time by intervention interaction
no effect
There was no interaction effect on the ataxia severity
PMID 38843619 · one of two readings recorded this
executive function, time by intervention interaction
increases
There were significant interaction effects for executive function (ƞ2 = 0.28-0.43)
PMID 38843619 · one of two readings recorded this
circulating miRNA expression, hsa-miR-1268a, -3605-3p, -555, and -6511a-3p
decreases
Specifically, hsa-miR-1268a, -3605-3p, -555, and -6511a-3p were significantly downregulated, while hsa-miR-324-3p and -539-5p showed significant upregulation
PMID 40187517 · one of two readings recorded this
circulating miRNA expression, hsa-miR-324-3p and -539-5p
increases
Specifically, hsa-miR-1268a, -3605-3p, -555, and -6511a-3p were significantly downregulated, while hsa-miR-324-3p and -539-5p showed significant upregulation
PMID 40187517 · one of two readings recorded this
Disease rate ratio for change in ALSFRS-R and survival (composite)
no effect
The disease rate ratio for change in ALSFRS-R and survival was 0·87 (95% credible interval 0·665-1·102, posterior probability of superiority 0·877)
PMID 40409314 · one of two readings recorded this